ELVN Stock Forecast & Price Target

Enliven Therapeutics is viewed favorably because ELVN-001 has shown strong early efficacy in heavily pretreated 2L+ CML, including a 61% MMR rate by 24 weeks in the 80 mg cohort, with activity that compared well against bosutinib and asciminib. The FDA-aligned ENABLE-2 Phase 3 design, with about 450 patients, a Week 24 MMR primary endpoint, and a >10% improvement threshold for statistical significance, appears de-risked by those Phase 1 data and by receipt of Fast Track Designation. Financially, the company ended 2Q26 with $895M in cash and equivalents, supporting runway into 2030 and giving it the balance-sheet strength to execute its CML program while advancing ELVN-002.

Enliven Therapeutics is exposed to substantial clinical and execution risk because its valuation depends on ELVN-001 and ELVN-002 advancing successfully through development and eventually gaining regulatory approval, yet the company explicitly faces the possibility of R&D, regulatory, and commercial setbacks. The negative outlook is reinforced by the chance that ELVN-001 may fail to secure approval, market uptake may be slower than anticipated, and pricing, reimbursement, or market access challenges could limit adoption even if development succeeds. Further pressure comes from emerging competitors and the risk of dilutive financing, which could weaken shareholder value over the medium to long term if additional capital is needed to support a still early-stage pipeline.